Baudax Bio, Inc. (BXRXQ)

Market Cap	52.00
Revenue (ttm)	1.27M
Net Income (ttm)	-7.61M
Shares Out	52.46M
EPS (ttm)	-1.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1
Average Volume	251
Open	0.0001
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	21.61
RSI	29.13
Earnings Date	n/a

About Baudax Bio

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB revers...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 9
• Stock Exchange: OTCMKTS
• Ticker Symbol: BXRXQ

Financial Performance

In 2022, Baudax Bio's revenue was $1.27 million, an increase of 17.50% compared to the previous year's $1.08 million. Losses were -$58.80 million, 197.4% more than in 2021.